OBJECTIVE: To evaluate the efficacy of IV iron supplementation of anemic, critically ill trauma patients. DESIGN: Multicenter, randomized, single-blind, placebo-controlled trial. SETTING: Four trauma ICUs. PATIENTS: Anemic (hemoglobin < 12 g/dL) trauma patients enrolled within 72 hours of ICU admission and with an expected ICU length of stay of more than or equal to 5 days. INTERVENTIONS: Randomization to iron sucrose 100 mg IV or placebo thrice weekly for up to 2 weeks. MEASUREMENTS AND MAIN RESULTS: A total of 150 patients were enrolled. Baseline iron markers were consistent with functional iron deficiency: 134 patients (89.3%) were hypoferremic, 51 (34.0%) were hyperferritinemic, and 64 (42.7%) demonstrated iron-deficient erythropoiesis as evidenced by an elevated erythrocyte zinc protoporphyrin concentration. The median baseline transferrin saturation was 8% (range, 2-58%). In the subgroup of patients who received all six doses of study drug (n = 57), the serum ferritin concentration increased significantly for the iron as compared with placebo group on both day 7 (808.0 ng/mL vs 457.0 ng/mL, respectively, p < 0.01) and day 14 (1,046.0 ng/mL vs 551.5 ng/mL, respectively, p < 0.01). There was no significant difference between groups in transferrin saturation, erythrocyte zinc protoporphyrin concentration, hemoglobin concentration, or packed RBC transfusion requirement. There was no significant difference between groups in the risk of infection, length of stay, or mortality. CONCLUSIONS: Iron supplementation increased the serum ferritin concentration significantly, but it had no discernible effect on transferrin saturation, iron-deficient erythropoiesis, hemoglobin concentration, or packed RBC transfusion requirement. Based on these data, routine IV iron supplementation of anemic, critically ill trauma patients cannot be recommended (NCT 01180894).
RCT Entities:
OBJECTIVE: To evaluate the efficacy of IV iron supplementation of anemic, critically ill traumapatients. DESIGN: Multicenter, randomized, single-blind, placebo-controlled trial. SETTING: Four trauma ICUs. PATIENTS: Anemic (hemoglobin < 12 g/dL) traumapatients enrolled within 72 hours of ICU admission and with an expected ICU length of stay of more than or equal to 5 days. INTERVENTIONS: Randomization to iron sucrose 100 mg IV or placebo thrice weekly for up to 2 weeks. MEASUREMENTS AND MAIN RESULTS: A total of 150 patients were enrolled. Baseline iron markers were consistent with functional iron deficiency: 134 patients (89.3%) were hypoferremic, 51 (34.0%) were hyperferritinemic, and 64 (42.7%) demonstrated iron-deficient erythropoiesis as evidenced by an elevated erythrocyte zinc protoporphyrin concentration. The median baseline transferrin saturation was 8% (range, 2-58%). In the subgroup of patients who received all six doses of study drug (n = 57), the serum ferritin concentration increased significantly for the iron as compared with placebo group on both day 7 (808.0 ng/mL vs 457.0 ng/mL, respectively, p < 0.01) and day 14 (1,046.0 ng/mL vs 551.5 ng/mL, respectively, p < 0.01). There was no significant difference between groups in transferrin saturation, erythrocyte zinc protoporphyrin concentration, hemoglobin concentration, or packed RBC transfusion requirement. There was no significant difference between groups in the risk of infection, length of stay, or mortality. CONCLUSIONS:Iron supplementation increased the serum ferritin concentration significantly, but it had no discernible effect on transferrin saturation, iron-deficient erythropoiesis, hemoglobin concentration, or packed RBC transfusion requirement. Based on these data, routine IV iron supplementation of anemic, critically ill traumapatients cannot be recommended (NCT 01180894).
Authors: Ines G Alamo; Kolenkode B Kannan; Michael A Smith; Philip A Efron; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2016-10 Impact factor: 3.313
Authors: Ines G Alamo; Kolenkode B Kannan; Letitia E Bible; Tyler J Loftus; Harry Ramos; Philip A Efron; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2017-04 Impact factor: 3.313
Authors: Ellen M Smith; Jennifer L Jones; Jenny E Han; Jessica A Alvarez; John H Sloan; Robert J Konrad; Susu M Zughaier; Greg S Martin; Thomas R Ziegler; Vin Tangpricha Journal: JPEN J Parenter Enteral Nutr Date: 2017-12-11 Impact factor: 4.016
Authors: Konrad Hoeft; Donald B Bloch; Jan A Graw; Rajeev Malhotra; Fumito Ichinose; Aranya Bagchi Journal: Anesthesiology Date: 2017-07 Impact factor: 7.892
Authors: Anders Perner; Anthony C Gordon; Daniel De Backer; George Dimopoulos; James A Russell; Jeffrey Lipman; Jens-Ulrik Jensen; John Myburgh; Mervyn Singer; Rinaldo Bellomo; Timothy Walsh Journal: Intensive Care Med Date: 2016-10-01 Impact factor: 17.440
Authors: Tyler J Loftus; Juan C Mira; Julie A Stortz; Tezcan Ozrazgat-Baslanti; Gabriella L Ghita; Zhongkai Wang; Babette A Brumback; Ricardo F Ungaro; Azra Bihorac; Christiaan Leeuwenburgh; Frederick A Moore; Lyle L Moldawer; Scott C Brakenridge; Philip A Efron; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2019-02 Impact factor: 3.313
Authors: Tyler J Loftus; Juan C Mira; Elizabeth S Miller; Kolenkode B Kannan; Jessica M Plazas; Daniel Delitto; Julie A Stortz; Jennifer E Hagen; Hari K Parvataneni; Kalia K Sadasivan; Scott C Brakenridge; Frederick A Moore; Lyle L Moldawer; Philip A Efron; Alicia M Mohr Journal: Am J Respir Crit Care Med Date: 2018-09-01 Impact factor: 21.405